Repligen Corp (RGEN) 24.77 $RGEN
12.9% Return Seen to Date on SmarTrend Repligen Call (RGEN)
Comtex SmarTrend(R) - Fri Feb 13, 9:30AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on January 8th, 2015 at $22.46. In approximately 1 month, Repligen has returned 12.87% as of today's recent price of $25.35.
RGEN: 24.77 (-0.73)
Repligen (RGEN) Upgraded From Hold to Buy
at The Street - Wed Feb 11, 3:40PM CST
Repligen (RGEN) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B-.
RGEN: 24.77 (-0.73)
Repligen (RGEN) Showing Signs Of Being Strong And Under The Radar
at The Street - Wed Feb 11, 10:09AM CST
Trade-Ideas LLC identified Repligen (RGEN) as a strong and under the radar candidate
RGEN: 24.77 (-0.73)
Repligen Completes Expansion of U.S. Facility
GlobeNewswire - Tue Feb 10, 8:06AM CST
Repligen Corporation (Nasdaq:RGEN) announced today that it has completed an 11,000 square foot expansion of its U.S. manufacturing facility. The expansion includes a dedicated space for the production and assembly of Repligen's Alternating Tangential Flow System ("the ATF System"
, the most recent addition to the Company's upstream bioprocessing product portfolio. The ATF System is a market-leading product line used to significantly increase cell density and product yield during the fermentation step of the biologic drug manufacturing process. The expansion includes areas for ATF System assembly, quality control and inventory, as well as cleanroom suites for the production of single-use ATF Systems in an ISO 7 environment that meets the high standards of Repligen's biopharmaceutical customers.
RGEN: 24.77 (-0.73)
Repligen to Present at 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 04, 6:30AM CST
Repligen Corporation (Nasdaq:RGEN) today announced that the Company will present at the 2015 Leerink Global Healthcare Conference to be held February 11-12 at the Waldorf Astoria hotel in New York. Management is scheduled to participate in an analyst-moderated "fireside chat" with investors at 2:40 p.m. EST on Thursday, February 12, 2015. A live audio webcast of this discussion will be accessible through the Investor Events section of Company's website. A replay of the webcast will also be accessible for a period of time following the event.
RGEN: 24.77 (-0.73)
Pfizer backs out of development deal with Repligen
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 7:37AM CST
RGEN: 24.77 (-0.73), PFE: 34.64 (-0.23)
Repligen (RGEN) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 8:31AM CST
Repligen (RGEN) Shares March Higher, Can It Continue?
RGEN: 24.77 (-0.73)
New chief at Repligen
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 6:59AM CST
RGEN: 24.77 (-0.73)
Repligen Corporation Names Tony Hunt as Next Chief Executive Officer
GlobeNewswire - Wed Jan 21, 6:00AM CST
Repligen Corporation (Nasdaq:RGEN) announced today that its Board of Directors has appointed Tony J. Hunt to be the Company's next Chief Executive Officer. Mr. Hunt, currently Repligen's Chief Operating Officer, will succeed Walter C. Herlihy, Ph.D., who will retire as President and CEO effective May 21, 2015, the date of the Company's Annual Meeting of Stockholders.
RGEN: 24.77 (-0.73)
Repligen awarded USD1m milestone payment from Pfizer for the development of compounds for spinal muscular atrophy
M2 - Fri Jan 09, 3:06AM CST
Life science company Repligen (NasdaqGS:RGEN) reported on Thursday the receipt of a USD1m milestone payment from Pfizer under an exclusive worldwide licensing agreement for the development of compounds to potentially treat spinal muscular atrophy (SMA), a neuromuscular disease in children under two.
RGEN: 24.77 (-0.73)
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 08, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
LOXO: 11.91 (-0.24), ELOS: 10.16 (+0.07), AMBA: 50.71 (-4.46), RGEN: 24.77 (-0.73), ADXS: 7.18 (+0.06), NBIX: 37.22 (+0.27), PDFS: 18.31 (+0.04), HALO: 14.73 (+0.23), VLCCF: 4.15 (-0.06), PKT: 8.99 (+0.11), ARNA: 4.55 (+0.02)
Repligen up on preliminary revenue numbers and 2015 guidance
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 12:29PM CST
RGEN: 24.77 (-0.73)
Repligen Receives Milestone Payment From Pfizer
GlobeNewswire - Thu Jan 08, 6:41AM CST
Repligen Corporation (Nasdaq:RGEN) announced today that on December 30, 2014, it received a $1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement" for the development of compounds to potentially treat spinal muscular atrophy (SMA), a neuromuscular disease that typically presents in children under age two. Since announcing the Agreement in January 2013, Repligen has received $7 million in upfront and milestone payments. Repligen remains eligible to receive up to $63 million in additional performance-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement.
RGEN: 24.77 (-0.73), PFE: 34.64 (-0.23)
Innovate Biopharmaceuticals Acquires Late-Stage Pancreatic Imaging Assets
Marketwired - Mon Jan 05, 10:07AM CST
Innovate Biopharmaceuticals, Inc. ("Innovate" has entered into an agreement to purchase all assets related to RG-1068, a synthetic version of human secretin from Repligen Corporation. Repligen has completed a Phase 3 study demonstrating that RG-1068 improved detection of pancreatic duct abnormalities in patients with known or suspected pancreatitis. The acquisition includes a New Drug Application (NDA) filed for RG-1068 with the U.S Food and Drug Administration (FDA), a Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMEA), and all related preclinical and clinical data and filings.
RGEN: 24.77 (-0.73)
Repligen Earnings Review: 18 Days after Announcement Shares Down 2.0% (RGEN)
Comtex SmarTrend(R) - Mon Nov 24, 9:09AM CST
Two weeks ago on November 6th, 2014 Repligen (NASDAQ:RGEN) reported earnings and analysts, on average, expected earnings of $0.04 on sales of $15.5 million. The company actually reported EPS of $0.04 on sales of $15.3 million, missing EPS estimates by $0.00 and matching revenue estimates. Shares of Repligen have slipped from $23.35 to $22.89, representing a loss of 2.0%, since the company reported earnings 18 days ago.
RGEN: 24.77 (-0.73)
Repligen Up 10.5% Since SmarTrend Uptrend Call (RGEN)
Comtex SmarTrend(R) - Thu Nov 20, 4:56PM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on October 6th, 2014 at $20.70. In approximately 2 month, Repligen has returned 10.51% as of today's recent price of $22.87.
RGEN: 24.77 (-0.73)
Repligen Earnings Hindsight: Down 0.2% in Last 11 Days (RGEN)
Comtex SmarTrend(R) - Mon Nov 17, 1:37PM CST
A week ago on November 6th, 2014 Repligen (NASDAQ:RGEN) reported earnings and analysts, on average, expected earnings of $0.04 on sales of $15.5 million. The company actually reported EPS of $0.04 on sales of $15.3 million, missing EPS estimates by $0.00 and matching revenue estimates. Shares of Repligen have slipped from $23.35 to $23.30, representing a loss of 0.2%, since the company reported earnings 11 days ago.
RGEN: 24.77 (-0.73)
Shares of RGEN Up 16.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Nov 13, 11:19AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on October 6th, 2014 at $20.70. In approximately 1 month, Repligen has returned 16.31% as of today's recent price of $24.07.
RGEN: 24.77 (-0.73)
Repligen to Present at Stifel Healthcare Conference 2014
GlobeNewswire - Wed Nov 12, 6:30AM CST
Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference 2014 on Wednesday, November 19 at 10:55 a.m. EST. The conference will be held at the New York Palace Hotel in New York City.
RGEN: 24.77 (-0.73)
12.9% Return Seen to Date on SmarTrend Repligen Call (RGEN)
Comtex SmarTrend(R) - Fri Feb 13, 9:30AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on January 8th, 2015 at $22.46. In approximately 1 month, Repligen has returned 12.87% as of today's recent price of $25.35.
RGEN: 24.77 (-0.73)
Repligen (RGEN) Upgraded From Hold to Buy
at The Street - Wed Feb 11, 3:40PM CST
Repligen (RGEN) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B-.
RGEN: 24.77 (-0.73)
Repligen (RGEN) Showing Signs Of Being Strong And Under The Radar
at The Street - Wed Feb 11, 10:09AM CST
Trade-Ideas LLC identified Repligen (RGEN) as a strong and under the radar candidate
RGEN: 24.77 (-0.73)
Repligen Completes Expansion of U.S. Facility
GlobeNewswire - Tue Feb 10, 8:06AM CST
Repligen Corporation (Nasdaq:RGEN) announced today that it has completed an 11,000 square foot expansion of its U.S. manufacturing facility. The expansion includes a dedicated space for the production and assembly of Repligen's Alternating Tangential Flow System ("the ATF System"
, the most recent addition to the Company's upstream bioprocessing product portfolio. The ATF System is a market-leading product line used to significantly increase cell density and product yield during the fermentation step of the biologic drug manufacturing process. The expansion includes areas for ATF System assembly, quality control and inventory, as well as cleanroom suites for the production of single-use ATF Systems in an ISO 7 environment that meets the high standards of Repligen's biopharmaceutical customers. RGEN: 24.77 (-0.73)
Repligen to Present at 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 04, 6:30AM CST
Repligen Corporation (Nasdaq:RGEN) today announced that the Company will present at the 2015 Leerink Global Healthcare Conference to be held February 11-12 at the Waldorf Astoria hotel in New York. Management is scheduled to participate in an analyst-moderated "fireside chat" with investors at 2:40 p.m. EST on Thursday, February 12, 2015. A live audio webcast of this discussion will be accessible through the Investor Events section of Company's website. A replay of the webcast will also be accessible for a period of time following the event.
RGEN: 24.77 (-0.73)
Pfizer backs out of development deal with Repligen
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 7:37AM CST
RGEN: 24.77 (-0.73), PFE: 34.64 (-0.23)
Repligen (RGEN) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 8:31AM CST
Repligen (RGEN) Shares March Higher, Can It Continue?
RGEN: 24.77 (-0.73)
New chief at Repligen
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 6:59AM CST
RGEN: 24.77 (-0.73)
Repligen Corporation Names Tony Hunt as Next Chief Executive Officer
GlobeNewswire - Wed Jan 21, 6:00AM CST
Repligen Corporation (Nasdaq:RGEN) announced today that its Board of Directors has appointed Tony J. Hunt to be the Company's next Chief Executive Officer. Mr. Hunt, currently Repligen's Chief Operating Officer, will succeed Walter C. Herlihy, Ph.D., who will retire as President and CEO effective May 21, 2015, the date of the Company's Annual Meeting of Stockholders.
RGEN: 24.77 (-0.73)
Repligen awarded USD1m milestone payment from Pfizer for the development of compounds for spinal muscular atrophy
M2 - Fri Jan 09, 3:06AM CST
Life science company Repligen (NasdaqGS:RGEN) reported on Thursday the receipt of a USD1m milestone payment from Pfizer under an exclusive worldwide licensing agreement for the development of compounds to potentially treat spinal muscular atrophy (SMA), a neuromuscular disease in children under two.
RGEN: 24.77 (-0.73)
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 08, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
LOXO: 11.91 (-0.24), ELOS: 10.16 (+0.07), AMBA: 50.71 (-4.46), RGEN: 24.77 (-0.73), ADXS: 7.18 (+0.06), NBIX: 37.22 (+0.27), PDFS: 18.31 (+0.04), HALO: 14.73 (+0.23), VLCCF: 4.15 (-0.06), PKT: 8.99 (+0.11), ARNA: 4.55 (+0.02)
Repligen up on preliminary revenue numbers and 2015 guidance
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 12:29PM CST
RGEN: 24.77 (-0.73)
Repligen Receives Milestone Payment From Pfizer
GlobeNewswire - Thu Jan 08, 6:41AM CST
Repligen Corporation (Nasdaq:RGEN) announced today that on December 30, 2014, it received a $1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement"
for the development of compounds to potentially treat spinal muscular atrophy (SMA), a neuromuscular disease that typically presents in children under age two. Since announcing the Agreement in January 2013, Repligen has received $7 million in upfront and milestone payments. Repligen remains eligible to receive up to $63 million in additional performance-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement. RGEN: 24.77 (-0.73), PFE: 34.64 (-0.23)
Innovate Biopharmaceuticals Acquires Late-Stage Pancreatic Imaging Assets
Marketwired - Mon Jan 05, 10:07AM CST
Innovate Biopharmaceuticals, Inc. ("Innovate"
has entered into an agreement to purchase all assets related to RG-1068, a synthetic version of human secretin from Repligen Corporation. Repligen has completed a Phase 3 study demonstrating that RG-1068 improved detection of pancreatic duct abnormalities in patients with known or suspected pancreatitis. The acquisition includes a New Drug Application (NDA) filed for RG-1068 with the U.S Food and Drug Administration (FDA), a Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMEA), and all related preclinical and clinical data and filings. RGEN: 24.77 (-0.73)
Repligen Earnings Review: 18 Days after Announcement Shares Down 2.0% (RGEN)
Comtex SmarTrend(R) - Mon Nov 24, 9:09AM CST
Two weeks ago on November 6th, 2014 Repligen (NASDAQ:RGEN) reported earnings and analysts, on average, expected earnings of $0.04 on sales of $15.5 million. The company actually reported EPS of $0.04 on sales of $15.3 million, missing EPS estimates by $0.00 and matching revenue estimates. Shares of Repligen have slipped from $23.35 to $22.89, representing a loss of 2.0%, since the company reported earnings 18 days ago.
RGEN: 24.77 (-0.73)
Repligen Up 10.5% Since SmarTrend Uptrend Call (RGEN)
Comtex SmarTrend(R) - Thu Nov 20, 4:56PM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on October 6th, 2014 at $20.70. In approximately 2 month, Repligen has returned 10.51% as of today's recent price of $22.87.
RGEN: 24.77 (-0.73)
Repligen Earnings Hindsight: Down 0.2% in Last 11 Days (RGEN)
Comtex SmarTrend(R) - Mon Nov 17, 1:37PM CST
A week ago on November 6th, 2014 Repligen (NASDAQ:RGEN) reported earnings and analysts, on average, expected earnings of $0.04 on sales of $15.5 million. The company actually reported EPS of $0.04 on sales of $15.3 million, missing EPS estimates by $0.00 and matching revenue estimates. Shares of Repligen have slipped from $23.35 to $23.30, representing a loss of 0.2%, since the company reported earnings 11 days ago.
RGEN: 24.77 (-0.73)
Shares of RGEN Up 16.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Nov 13, 11:19AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on October 6th, 2014 at $20.70. In approximately 1 month, Repligen has returned 16.31% as of today's recent price of $24.07.
RGEN: 24.77 (-0.73)
Repligen to Present at Stifel Healthcare Conference 2014
GlobeNewswire - Wed Nov 12, 6:30AM CST
Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference 2014 on Wednesday, November 19 at 10:55 a.m. EST. The conference will be held at the New York Palace Hotel in New York City.
RGEN: 24.77 (-0.73)
